Anoop Manjunath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anoop Manjunath has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Gunsagar Singh Gulati
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
4 shared publications - Ankit Salhotra
Department of Urology, UCSF, San Francisco, CA, USA
3 shared publications - Ishan Kumar
Stanford University Stanford University School of Medicine Stanford, CA, USA
3 shared publications - Aaron M. Newman
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA.
2 shared publications Angelina Seffens
Department of Pediatrics, Stanford University School of Medicine/Stanford Children’s Hospital, Palo Alto, USA
2 shared publicationsArya Gowda
Stanford University School of Medicine, Stanford, USA
2 shared publications
Latest Publications
- Open Access
- 1 January 2024
- Published by Oxford University Press (OUP) in Journal of Law and the Biosciences
- Vol. 11 (1) , lsae005
Illegal interlocks among life science company boards of directors
Competition between life science companies is critical to ensure innovative therapies are efficiently developed. Anticompetitive behavior may harm scientific progress and, ultimately, patients. One well-established category of anticompetitive behavior is the ‘interlocking directorate’. It is illegal for companies’ directors to ‘interlock’ by also serving on the boards of competitors. We evaluated overlaps in the board membership of 2,241 public life science companies since 2000. We show that a robust network of interlocking companies is present among these firms. At any given time, 10–20 percent of board members are interlocked; the number of interlocks has more than doubled in the last two decades. Over half of these interlocked firms report over $5 million in historical revenue, exceeding a legal threshold that makes an interlocking directorate a violation of antitrust law. Those interlocks are only illegal if the companies compete, even in part. Using the disease categories for which companies have sponsored clinical trials, we discover that a few markets are responsible for a large fraction of interlocks. We show that in dozens of cases, companies share directors with the very firms they identify as their biggest competitive threats. We provide a data-driven roadmap for policymakers, regulators, and companies to further investigate the contribution of anticompetitive behavior to increased healthcare costs and to enforce the law against illegal interlocks between firms.
- 1 January 2024
- Published by Oxford University Press (OUP) in Journal of Law and the Biosciences
- Vol. 11 (1) , lsae005
Open AccessIllegal interlocks among life science company boards of directors
Competition between life science companies is critical to ensure innovative therapies are efficiently developed. Anticompetitive behavior may harm scientific progress and, ultimately, patients. One well-established category of anticompetitive behavior is the ‘interlocking directorate’. It is illegal for companies’ directors to ‘interlock’ by also serving on the boards of competitors. We evaluated overlaps in the board membership of 2,241 public life science companies since 2000. We show that a robust network of interlocking companies is present among these firms. At any given time, 10–20 percent of board members are interlocked; the number of interlocks has more than doubled in the last two decades. Over half of these interlocked firms report over $5 million in historical revenue, exceeding a legal threshold that makes an interlocking directorate a violation of antitrust law. Those interlocks are only illegal if the companies compete, even in part. Using the disease categories for which companies have sponsored clinical trials, we discover that a few markets are responsible for a large fraction of interlocks. We show that in dozens of cases, companies share directors with the very firms they identify as their biggest competitive threats. We provide a data-driven roadmap for policymakers, regulators, and companies to further investigate the contribution of anticompetitive behavior to increased healthcare costs and to enforce the law against illegal interlocks between firms.
- 16 May 2023
- Published by Springer Nature in Nature Biotechnology
- Vol. 41 (5) , 610-614
Who counts as an inventor? Seniority and gender in 430,000 biomedical inventor–researcher teams
- 16 May 2023
- Published by Springer Nature in Nature Biotechnology
- Vol. 41 (5) , 610-614
Who counts as an inventor? Seniority and gender in 430,000 biomedical inventor–researcher teams
- 10 June 2021
- Published by Springer Nature in Nature Biotechnology
- Vol. 39 (6) , 678-683
Comprehensive analysis of 2.4 million patent-to-research citations maps the biomedical innovation and translation landscape
- 10 June 2021
- Published by Springer Nature in Nature Biotechnology
- Vol. 39 (6) , 678-683
Comprehensive analysis of 2.4 million patent-to-research citations maps the biomedical innovation and translation landscape
- Top Cited PapersOpen Access
- 13 August 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-18
Elucidating the fundamental fibrotic processes driving abdominal adhesion formation
Adhesions are fibrotic scars that form between abdominal organs following surgery or infection, and may cause bowel obstruction, chronic pain, or infertility. Our understanding of adhesion biology is limited, which explains the paucity of anti-adhesion treatments. Here we present a systematic analysis of mouse and human adhesion tissues. First, we show that adhesions derive primarily from the visceral peritoneum, consistent with our clinical experience that adhesions form primarily following laparotomy rather than laparoscopy. Second, adhesions are formed by poly-clonal proliferating tissue-resident fibroblasts. Third, using single cell RNA-sequencing, we identify heterogeneity among adhesion fibroblasts, which is more pronounced at early timepoints. Fourth, JUN promotes adhesion formation and results in upregulation of PDGFRA expression. With JUN suppression, adhesion formation is diminished. Our findings support JUN as a therapeutic target to prevent adhesions. An anti-JUN therapy that could be applied intra-operatively to prevent adhesion formation could dramatically improve the lives of surgical patients.
- 13 August 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-18
Top Cited PapersOpen AccessElucidating the fundamental fibrotic processes driving abdominal adhesion formation
Adhesions are fibrotic scars that form between abdominal organs following surgery or infection, and may cause bowel obstruction, chronic pain, or infertility. Our understanding of adhesion biology is limited, which explains the paucity of anti-adhesion treatments. Here we present a systematic analysis of mouse and human adhesion tissues. First, we show that adhesions derive primarily from the visceral peritoneum, consistent with our clinical experience that adhesions form primarily following laparotomy rather than laparoscopy. Second, adhesions are formed by poly-clonal proliferating tissue-resident fibroblasts. Third, using single cell RNA-sequencing, we identify heterogeneity among adhesion fibroblasts, which is more pronounced at early timepoints. Fourth, JUN promotes adhesion formation and results in upregulation of PDGFRA expression. With JUN suppression, adhesion formation is diminished. Our findings support JUN as a therapeutic target to prevent adhesions. An anti-JUN therapy that could be applied intra-operatively to prevent adhesion formation could dramatically improve the lives of surgical patients.
- Top Cited Papers
- 24 January 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 367 (6476) , 405-411
Single-cell transcriptional diversity is a hallmark of developmental potential
More diversity at the top: A detailed knowledge of cell differentiation hierarchies is important for understanding diverse biological processes such as organ development, tissue regeneration, and cancer. Single-cell RNA sequencing can help elucidate these hierarchies, but it requires reliable computational methods for predicting cell lineage trajectories. Gulati et al. developed CytoTRACE, a computational framework based on the simple observation that transcriptional diversity—the number of genes expressed in a cell—decreases during differentiation. CytoTRACE outperformed other methods in several test cases and was successfully applied to study cellular hierarchies in healthy and tumor tissue. Science , this issue p. 405
- 24 January 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 367 (6476) , 405-411
Top Cited PapersSingle-cell transcriptional diversity is a hallmark of developmental potential
More diversity at the top: A detailed knowledge of cell differentiation hierarchies is important for understanding diverse biological processes such as organ development, tissue regeneration, and cancer. Single-cell RNA sequencing can help elucidate these hierarchies, but it requires reliable computational methods for predicting cell lineage trajectories. Gulati et al. developed CytoTRACE, a computational framework based on the simple observation that transcriptional diversity—the number of genes expressed in a cell—decreases during differentiation. CytoTRACE outperformed other methods in several test cases and was successfully applied to study cellular hierarchies in healthy and tumor tissue. Science , this issue p. 405
- Open Access
Single-cell transcriptional diversity is a hallmark of developmental potential
Single-cell RNA-sequencing (scRNA-seq) is a powerful approach for reconstructing cellular differentiation trajectories. However, inferring both the state and direction of differentiation without prior knowledge has remained challenging. Here we describe a simple yet robust determinant of developmental potential—the number of detectably expressed genes per cell— and leverage this measure of transcriptional diversity to develop a new framework for predicting ordered differentiation states from scRNA-seq data. When evaluated on ~150,000 single-cell transcriptomes spanning 53 lineages and five species, our approach, called CytoTRACE, outperformed previous methods and ~19,000 molecular signatures for resolving experimentally-confirmed developmental trajectories. In addition, it enabled unbiased identification of tissue-resident stem cells, including cells with long-term regenerative potential. When used to analyze human breast tumors, we discovered candidate genes associated with less-differentiated luminal progenitor cells and validated GULP1 as a novel gene involved in tumorigenesis. Our study establishes a key RNA-based correlate of developmental potential and provides a new platform for robust delineation of cellular hierarchies ( https://cytotrace.stanford.edu ).
Open AccessSingle-cell transcriptional diversity is a hallmark of developmental potential
Single-cell RNA-sequencing (scRNA-seq) is a powerful approach for reconstructing cellular differentiation trajectories. However, inferring both the state and direction of differentiation without prior knowledge has remained challenging. Here we describe a simple yet robust determinant of developmental potential—the number of detectably expressed genes per cell— and leverage this measure of transcriptional diversity to develop a new framework for predicting ordered differentiation states from scRNA-seq data. When evaluated on ~150,000 single-cell transcriptomes spanning 53 lineages and five species, our approach, called CytoTRACE, outperformed previous methods and ~19,000 molecular signatures for resolving experimentally-confirmed developmental trajectories. In addition, it enabled unbiased identification of tissue-resident stem cells, including cells with long-term regenerative potential. When used to analyze human breast tumors, we discovered candidate genes associated with less-differentiated luminal progenitor cells and validated GULP1 as a novel gene involved in tumorigenesis. Our study establishes a key RNA-based correlate of developmental potential and provides a new platform for robust delineation of cellular hierarchies ( https://cytotrace.stanford.edu ).
- Top Cited Papers
Identification of the Human Skeletal Stem Cell
- 10 May 2018
- Published by Springer Nature in Nature Protocols
- Vol. 13 (6) , 1294-1309
Isolation and functional assessment of mouse skeletal stem cell lineage
A flow cytometry–based approach using eight surface markers is used to distinguish cells of the skeletal stem cell lineage. Renal subcapsular transplantation and in vitro colony-formation assays are also described for cell characterization. There are limited methods available to study skeletal stem, progenitor, and progeny cell activity in normal and diseased contexts. Most protocols for skeletal stem cell isolation are based on the extent to which cells adhere to plastic or whether they express a limited repertoire of surface markers. Here, we describe a flow cytometry–based approach that does not require in vitro selection and that uses eight surface markers to distinguish and isolate mouse skeletal stem cells (mSSCs); bone, cartilage, and stromal progenitors (mBCSPs); and five downstream differentiated subtypes, including chondroprogenitors, two types of osteoprogenitors, and two types of hematopoiesis-supportive stroma. We provide instructions for the optimal mechanical and chemical digestion of bone and bone marrow, as well as the subsequent flow-cytometry-activated cell sorting (FACS) gating schemes required to maximally yield viable skeletal-lineage cells. We also describe a methodology for renal subcapsular transplantation and in vitro colony-formation assays on the isolated mSSCs. The isolation of mSSCs can be completed in 9 h, with at least 1 h more required for transplantation. Experience with flow cytometry and mouse surgical procedures is recommended before attempting the protocol. Our system has wide applications and has already been used to study skeletal response to fracture, diabetes, and osteoarthritis, as well as hematopoietic stem cell–niche interactions in the bone marrow.
- 10 May 2018
- Published by Springer Nature in Nature Protocols
- Vol. 13 (6) , 1294-1309
Isolation and functional assessment of mouse skeletal stem cell lineage
A flow cytometry–based approach using eight surface markers is used to distinguish cells of the skeletal stem cell lineage. Renal subcapsular transplantation and in vitro colony-formation assays are also described for cell characterization. There are limited methods available to study skeletal stem, progenitor, and progeny cell activity in normal and diseased contexts. Most protocols for skeletal stem cell isolation are based on the extent to which cells adhere to plastic or whether they express a limited repertoire of surface markers. Here, we describe a flow cytometry–based approach that does not require in vitro selection and that uses eight surface markers to distinguish and isolate mouse skeletal stem cells (mSSCs); bone, cartilage, and stromal progenitors (mBCSPs); and five downstream differentiated subtypes, including chondroprogenitors, two types of osteoprogenitors, and two types of hematopoiesis-supportive stroma. We provide instructions for the optimal mechanical and chemical digestion of bone and bone marrow, as well as the subsequent flow-cytometry-activated cell sorting (FACS) gating schemes required to maximally yield viable skeletal-lineage cells. We also describe a methodology for renal subcapsular transplantation and in vitro colony-formation assays on the isolated mSSCs. The isolation of mSSCs can be completed in 9 h, with at least 1 h more required for transplantation. Experience with flow cytometry and mouse surgical procedures is recommended before attempting the protocol. Our system has wide applications and has already been used to study skeletal response to fracture, diabetes, and osteoarthritis, as well as hematopoietic stem cell–niche interactions in the bone marrow.
- 1 October 2015
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 41 (10) , 2774-2782
The Effect of Short Duration Ultrasound Pulses on the Interaction Between Individual Microbubbles and Fibrin Clots
- 1 October 2015
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 41 (10) , 2774-2782
The Effect of Short Duration Ultrasound Pulses on the Interaction Between Individual Microbubbles and Fibrin Clots
- 1 September 2014
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 40 (9) , 2134-2150
Interactions between Individual Ultrasound-Stimulated Microbubbles and Fibrin Clots
- 1 September 2014
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 40 (9) , 2134-2150
Interactions between Individual Ultrasound-Stimulated Microbubbles and Fibrin Clots